Business Wire

Denodo Continues Exceptional Growth Trajectory Evidenced by Strong Year-End Momentum

19.3.2020 11:00:00 EET | Business Wire | Press release

Share

Denodo, the leader in data virtualization, today announced that its impressive worldwide growth continued in 2019 as evidenced by a 50 percent increase in year-over-year revenue. New customer acquisition, aided by Amazon, Azure and Google Marketplaces, played a key role as subscription and expansion among existing global customers contributed to the 52 percent surge over the previous year. Interest in the award-winning Denodo Platform expanded globally with customers from around the world factoring into Denodo’s profitability. In particular, revenue from the APAC region grew 275 percent and now makes up more than 10 percent of the Company’s total revenue.

Employee headcount expanded 30 percent to support this worldwide growth. The data virtualization provider also extended its worldwide footprint by opening offices in China, Mexico, and Canada bringing the total number of worldwide offices to 19. Strategic technology and consulting alliances also intensified as marked by a 56 percent increase in new partner agreements signed and significant expansion of current partnerships, bringing a 192 percent increase in revenue from this important partner channel.

During this period, Denodo added advanced capabilities to its Denodo Platform so companies could simply and quickly deliver data science, cloud migration, and logical data lake projects. With advances across performance, cloud, and data catalog capabilities, Denodo 7 addresses the mounting data volumes from diverse data sources accelerating digital transformation projects. New customers from virtually every industry and geography joined the Company’s already impressive roster and include leading brands such as PetSmart, University of Rochester Medical Center, UBS, The Bank of New York Mellon, and Walmart de México y Centroamérica.

Denodo was recognized in the Gartner Peer Insights “Voice of the Customer”: Data Integration Tools, 4 December, 2019 as the only data integration product that was recommended by 100 percent of the reviewers. With an overall rating of 4.5 out of 5, Denodo received the second highest ranking of the fifteen eligible vendors for Evaluation and Contracting. Further, Denodo was recognized for the second consecutive year as a Challenger in the 2019 Gartner Magic Quadrant for Data Integration Tools, representing the growing importance of Data Virtualization in the broader data integration market. The Company was also named the best data virtualization solution in Database Trends and Applications 2019 Readers’ Choice Awards 2019.

“Our goal has always been to help our worldwide customers provide order to the complexity of data management and take it to the next level,” said Angel Viña, founder and CEO of Denodo. “The remarkable growth we achieved in 2019, demonstrated by the numerous industry analyst accolades and new customers who are leveraging Denodo to keep up with the changing data landscape, is a testament to how we are improving the bottom-line. This year we look forward to adding even more capabilities, including greater support for artificial intelligence and machine learning, to support these evolving trends and grow our already impressive global presence and partner network.”

Please Tweet: News: #datavirtualization leader @denodo announces double-digit revenue growth and significant #cloud adoption @awscloud @gcpcloud @azure https://buff.ly/2Ujx48x

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release

Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I

Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release

Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye